CANIFERON
LIVE

Serial Number

79327653

Owner

ILC Therapeutics Limited

Attorney

Brian M. Davis

Filing Date

Sep 16, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CANIFERON Trademark

Serial Number: 79327653 • Registration: 6966132

CANIFERON is a trademark filed by ILC Therapeutics Limited on September 16, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ILC Therapeutics Limited (2 trademarks)

Biocity Scotland, Bo'ness Road

Entity Type: 99

Trademark Details

Filing Date

September 16, 2021

Registration Date

January 31, 2023

Published for Opposition

November 15, 2022

Goods & Services

[ Pharmaceuticals, medical and veterinary preparations for use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; pharmaceutical, medical and veterinary preparations for prevention, diagnosis and treatment of skin diseases; pharmaceutical, medical and veterinary preparations for dermatitis; pharmaceutical, medical and veterinary preparations for inflammatory diseases; medicines for veterinary purposes for use in the treatment of cancer, skin disorders and inflammatory diseases; pharmaceutical, medical and ] veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, dermatitis, skin diseases, * pruritic conditions, coronavirus and allergies * [ and inflammatory diseases; pharmaceutical, medical and veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, dermatitis, skin diseases and inflammatory diseases, for animals; pharmaceutical, medical and veterinary drugs for use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biological preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; biological reagents being pharmaceutical preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; biological tissue cultures for medical use; biochemical preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; anti-viral agents; diagnostic preparations for medical and veterinary purposes; clinical diagnostic reagents for medical and veterinary purposes; immunoassay reagents for medical use ]

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
May 13, 2025 NURC
LIMITATION FROM THE IB EXAMINED AND ENTERED
May 1, 2025 LIME
CORRECTION UNDER SECTION 7 - PROCESSED
Apr 24, 2025 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 24, 2025 APRE
LIMITATION OF GOODS RECEIVED FROM IB
Oct 11, 2024 LIMG
FINAL DECISION TRANSACTION PROCESSED BY IB
May 30, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 5, 2023 FICS
FINAL DISPOSITION PROCESSED
May 5, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 30, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 31, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 31, 2023 R.PR
ASSIGNED TO EXAMINER
Dec 13, 2022 DOCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 15, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 26, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 11, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 4, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 3, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 3, 2022 TROA
REFUSAL PROCESSED BY IB
Jul 19, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 24, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 24, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 22, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jun 21, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 21, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 14, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 10, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 9, 2021 REPR